Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya(R) for PTSD, Following FDA Meeting

NEW YORK, Nov 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- Primary Endpoint Will be Mean Change from Baseline in CAPS-5 at Week 12, Instead of Week 4 Results from Added [...]